Antineoplastic agent: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett |
||
| Line 83: | Line 83: | ||
;Anti-EpCAM | ;Anti-EpCAM | ||
* [[Edrecolomab]] is monclonal antibody against EpCAM | * [[Edrecolomab]] is monclonal antibody against EpCAM ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_002345 Entrez protein]). Edrecolomab is a "anticolorectal carcinoma antibody for treatment of advanced [[colorectal cancer|colorectal carcinoma]]".<ref>{{MeSH|edrecolomab [Substance Name]}}</ref> | ||
;Anti-ERBB2 | ;Anti-ERBB2 | ||
| Line 89: | Line 89: | ||
;Anti-CD3 and anti-EpCAM | ;Anti-CD3 and anti-EpCAM | ||
* [[Catumaxomab]]. Is a monoclonal antibody against CD3 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NM_000732 Entrez protein])and EpCAM ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_002345 Entrez protein]). "Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular cytokine release induced by therapeutic antibodies".<ref>{{MeSH|Catumaxomab [Substance Name]}}</ref> | |||
; Anti-MS4A1 (CD20 antigen) | ; Anti-MS4A1 (CD20 antigen) | ||
| Line 101: | Line 101: | ||
;Anti-VEGF | ;Anti-VEGF | ||
* [[Bevacizumab]] is an "anti-VEGF ( | * [[Bevacizumab]] is an "anti-VEGF ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_001020537 Entrez protein]) monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".<ref>{{MeSH|Bevacizumab [Substance Name]}}</ref> | ||
[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_001020537 Entrez protein]) monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".<ref>{{MeSH|Bevacizumab [Substance Name]}}</ref> | |||
==== Sensitizers used in photodynamic/radiation therapy==== | ==== Sensitizers used in photodynamic/radiation therapy==== | ||
Revision as of 21:22, 4 February 2009
In medicine, antineoplastic agents are "substances that inhibit or prevent the proliferation of neoplasms".[1] Generally, antineoplastic agents are for treating malignant neoplasms such as cancers and sarcomas.
Classification
This classification is based on World Health Organization's Collaborating Centre for Drug Statistics Methodology.[2]
Alkylating agents
ATC/DDD group L01A. Alkylating antineoplastic agents are a "class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood."[3]
Nitrogen mustard analogues
ATC/DDD group L01AA.
Alkyl sulfonates
ATC/DDD group L01AB.
Ethylene imines
ATC/DDD group L01AC.
Nitrosoureas
ATC/DDD group L01AD.
Epoxides
ATC/DDD group L01AG.
Other alkylating agents
ATC/DDD group L01AX.
Antimetabolites
ATC/DDD group L01B. Antineoplastic antimetabolites are "antimetabolites that are useful in cancer chemotherapy."[4]
Folic acid analogues
ATC/DDD group L01BA.
Purine analogues
ATC/DDD group L01BB.
Pyrimidine analogues
ATC/DDD group L01BC.
Plant alkaloids and other natural products
ATC/DDD group L01C.
Vinca alkaloids and analogues
ATC/DDD group L01CA.
Podophyllotoxin derivatives
ATC/DDD group L01CB.
Colchicine derivatives
ATC/DDD group L01CC.
Taxanes
ATC/DDD group L01CD.
Other plant alkaloids and natural products
ATC/DDD group L01CX.
ATC/DDD group L01D.
Actinomycines
ATC/DDD group L01DA.
ATC/DDD group L01DB.
Other cytotoxic antibiotics
ATC/DDD group L01DC.
Other antineoplastic agents
ATC/DDD group L01X.
Platinum compounds
ATC/DDD group L01XA.
Methylhydrazines
ATC/DDD group L01XB.
Monoclonal antibodies
ATC/DDD group L01XC. Examples include:
- Anti-EGRF
- Panitumumab is an "antibody that blocks receptors for epidermal growth factor (Entrez protein); approved for advanced colon cancer".[5]
- Anti-EpCAM
- Edrecolomab is monclonal antibody against EpCAM (Entrez protein). Edrecolomab is a "anticolorectal carcinoma antibody for treatment of advanced colorectal carcinoma".[6]
- Anti-ERBB2
- Trastuzumab is a "HER2 (Entrez protein) antibody that lengthens remission time in metastatic breast cancer."[7]
- Anti-CD3 and anti-EpCAM
- Catumaxomab. Is a monoclonal antibody against CD3 (Entrez protein)and EpCAM (Entrez protein). "Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular cytokine release induced by therapeutic antibodies".[8]
- Anti-MS4A1 (CD20 antigen)
- Rituximab is a "genetically engineered anti-CD20 (Entrez protein) antibody for the treatment of B-cell lymphoma".[9]
- Anti-SIGLEC3 (CD33)
- Gemtuzumab is an "anti-CD33 (Entrez protein) antibody calicheamicin conjugate".[10]
- Anti-CD52
- Alemtuzumab is a "a therapeutic antibody directed against the CDw52 antigen (Entrez protein) expressed by the lymphocytes and has proven lytic abilities both in vitro and in vivo; has been sequenced".[11]
- Anti-VEGF
- Bevacizumab is an "anti-VEGF (Entrez protein) monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".[12]
Sensitizers used in photodynamic/radiation therapy
ATC/DDD group L01XD.
Protein kinase inhibitors
ATC/DDD group L01XE. Examples include matinib, gefitinib, erlotinib, sunitinib, sorafenib, dasatinib, lapatinib, nilotinib, and temsirolimus.
References
- ↑ Anonymous (2024), Antineoplastic agent (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous. WHO Collaborating Centre for Drug Statistics Methodology. World Health Organization. Retrieved on 2009-02-04.
- ↑ Anonymous (2024), Antineoplastic Agents, Alkylating (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Antineoplastic Agents, Alkylating (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Panitumumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), edrecolomab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Trastuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Catumaxomab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Rituximab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Gemtuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Alemtuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Bevacizumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.